Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Equillium Inc (GB:0A4D)
LSE:0A4D
Holding GB:0A4D?
Track your performance easily
0A4D Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.49 - $3.12
Previous Close$0.85
Volume200.00
Average Volume (3M)2.17K
Market Cap
$30.29M
Enterprise Value-$2.40M
Total Cash (Recent Filing)$33.30M
Total Debt (Recent Filing)$609.00K
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Nov 12, 2024EPS Estimate
$0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding35,424,388
10 Day Avg. Volume36
30 Day Avg. Volume2,172
Standard Deviation0.37
R-Squared0.01
Alpha0.00804
Financial Highlights & Ratios
Price to Book (P/B)1.35
Price to Sales (P/S)0.71
Price to Cash Flow (P/CF)10.40
P/FCF Ratio11.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.06
Enterprise Value/Gross Profit-0.07
Enterprise Value/Ebitda0.29
Forecast
1Y Price Target
$5.00Price Target Upside485.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Equillium News
PremiumPre-Earnings
Is EQ a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Clinical TrialsEquillium received a positive recommendation from the Independent Data Monitoring Committee (IDMC) based on its review of the interim results from the Phase 3 EQUATOR study evaluating itolizumab in subjects with acute graft-vs.-host disease (aGVHD).
Financial PerformanceIf Ono Pharmaceutical Co. Ltd. exercises its option on itolizumab, this would result in a payment of ¥5B—roughly $32.2M based on recent exchange rates—and significantly improve Equillium's balance sheet strength.
Product DevelopmentEQ101 recently reported positive topline data from an open-label study, exceeding KOL's expectations in severe patients and indicating proof-of-concept in alopecia with a 20% response rate.
Bears Say
Approval RisksFailure to obtain approval for itolizumab.
Clinical DelaysDelays in generating clinical data with itolizumab.
Safety ConcernsSafety profile is not as clean as desired, given several discontinuations and presence of lymphocytopenia.
---
Options Prices
Currently, No data available
---
Ownership Overview
31.27% Insiders
14.69% Mutual Funds
17.38% Other Institutional Investors
36.65% Public Companies and
Individual Investors
0A4D FAQ
What was Equillium Inc’s price range in the past 12 months?
Equillium Inc lowest share price was $0.49 and its highest was $3.12 in the past 12 months.
What is Equillium Inc’s market cap?
Currently, no data Available
When is Equillium Inc’s upcoming earnings report date?
Equillium Inc’s upcoming earnings report date is Nov 12, 2024 which is in 54 days.
How were Equillium Inc’s earnings last quarter?
Equillium Inc released its earnings results on Aug 08, 2024. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.15 by $0.16.
Is Equillium Inc overvalued?
According to Wall Street analysts Equillium Inc’s price is currently Undervalued.
Does Equillium Inc pay dividends?
Equillium Inc does not currently pay dividends.
What is Equillium Inc’s EPS estimate?
Equillium Inc’s EPS estimate is $0.29.
How many shares outstanding does Equillium Inc have?
Equillium Inc has 35,424,390 shares outstanding.
What happened to Equillium Inc’s price movement after its last earnings report?
Equillium Inc reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.15. Following the earnings report the stock price went down -5.499%.
Which hedge fund is a major shareholder of Equillium Inc?
Among the largest hedge funds holding Equillium Inc’s share is Cota Capital Management, LLC. It holds Equillium Inc’s shares valued at 390K.
---
Equillium Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (485.48% Upside)
$5.00 (485.48% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.01%
12-Months-Change
Fundamentals
Return on Equity
-33.67%
Trailing 12-Months
Asset Growth
-27.06%
Trailing 12-Months
Company Description
Equillium Inc
Equillium, Inc. is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. Its product pipeline include EQ001, is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.
---
0A4D Stock 12 Month Forecast
Average Price Target
$5.00
▲(485.48% Upside)
Technical Analysis
Equillium
―
Adaptimmune Therapeutics
―
Arcutis Biotherapeutics
―
Immatics
―
Kiniksa Pharmaceuticals
―
Best Analysts Covering 0A4D
1 Year
1 Year Success Rate
7/22 ratings generated profit
1 Year Average Return
-10.66%
reiterated a buy rating last month
Copying Thomas Smith's trades and holding each position for 1 Year would result in 31.82% of your transactions generating a profit, with an average return of -10.66% per trade.
---